SCHEMBL933430

SCHEMBL933430

CCOC(=O)C(O)=CC(=O)c1ccc(C)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
KMT2A Q03164 6/20 0.43
MEN1 O00255 4/20 0.43
MAPT P10636 6/20 0.42
KDM4E B2RXH2 1/20 0.40
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
ALDH1A1 P00352 2/20 0.39
DGAT1 O75907 1/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 2/20 0.37
MAPK1 P28482 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CA2 P00918 1/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933429 1.00 HDAC1 (0.44) HDAC1HDAC6KMT2AMEN1MAPT
SCHEMBL2232110 0.87 HDAC1 (0.49) HDAC1HDAC6KMT2AMEN1MAPT
SCHEMBL2232113 0.87 HDAC1 (0.49) HDAC1HDAC6KMT2AMEN1MAPT
SCHEMBL934580 0.86 NNMT (0.49) KMT2AMEN1MAPTKDM4ECA12
SCHEMBL934582 0.86 NNMT (0.49) KMT2AMEN1MAPTKDM4ECA12
SCHEMBL933903 0.84 ALDH1A1 (0.45) MAPTCA12CA1CA9ALDH1A1
SCHEMBL933904 0.84 ALDH1A1 (0.45) MAPTCA12CA1CA9ALDH1A1
SCHEMBL1058878 0.83 ALDH1A1 (0.49) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL1058879 0.83 ALDH1A1 (0.49) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL6115747 0.81 ALDH1A1 (0.48) KMT2AMEN1MAPTKDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120128630-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE VIVALIS (FR) 2012-05-24 US disclosed
EP-2451800-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE Vivalis (FR) 2012-05-16 EP disclosed
WO-2011004017-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE VIVALIS (FR) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128630-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE NAT1, POLM, PYGL HDAC1 454/4885HDAC6 433/4885KMT2A 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.